Arrayit Diagnostics Licenses Ovarian Cancer Biomarkers from Wayne State U | GenomeWeb

NEW YORK (GenomeWeb News) – Arrayit Diagnostics said today that it has exclusively licensed ovarian cancer biomarker intellectual property from Wayne State University.

Under the agreement, Houston-based Arrayit Diagnostics, a majority-owned subsidiary of Sunnyvale, Calif.-based Arrayit Corporation, gains exclusive worldwide rights to develop and commercialize a microarray-based diagnostic test using the biomarkers, which were developed by WSU researchers Michael Tainsky, Sorin Draghici, and Madhumita Chatterjee.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.